Skip to main content
. 2023 Jan 20;36:10647. doi: 10.3389/ti.2023.10647

TABLE 3.

Linear mixed model for eGFR trajectory in the first year post-transplant.

Value Standard error p-value (GVIF1/2df)2
(Intercept) 74.82 9.06 <0.001
Time (days) 1.85
 Day 1 – day 50 4.22 2.31 0.067
 Day 50 – day 100 30.90 3.59 <0.001
 After day 100 11.75 1.80 <0.001
Recipient ipsilateral AIC score (per 1000 units) 0.02 0.18 0.919 2.37
Recipient age (per year) −0.23 0.12 0.064 1.61
Recipient sex 1.36
 Male Ref
 Female 3.52 2.08 0.094
Recipient diabetes 1.19
 No Ref
 Yes 0.33 1.93 0.865
Recipient smoking 1.30
 Never Ref
 Currently −0.04 2.92 0.988
 Quit −0.08 2.25 0.973
Previous kidney transplant 2.22
 No Ref
 Yes 0.43 3.51 0.902
Total dialysis duration (per month) 0.03 0.06 0.621 2.54
Coronary artery disease 1.37
 None Ref
 Single vessel 5.67 3.45 0.103
 Double vessel 5.87 4.58 0.203
 Triple vessel −2.81 3.75 0.455
Peripheral arterial disease 1.38
 No Ref
 Yes −4.51 4.41 0.309
Donor type 3.24
 Living Ref
 DCD −14.41 4.918 0.003
 DBD −7.32 5.016 0.137
Donor age (per year) −0.29 0.08 <0.001 1.39
Donor diabetes 1.35
 No Ref
 Yes −6.69 6.06 0.272
Donor last creatinine (per µmol/l) −0.04 0.03 0.150 1.74
Pre-emptive transplant 2.12
 Yes Ref
 No −4.15 2.60 0.114
Cold preservation 2.56
 Static cold storage Ref
 Hypothermic machine perfusion 0.10 3.00 0.972
Total HLA mismatch (per 1 mismatch) −0.21 0.63 0.744 1.23
vPRA (per %) −0.02 0.04 0.634 2.32
Cold ischemic time (per minute) 0.00 0.01 0.917 4.87
Postoperative dialysis 2.60
 No Ref
 Yes −9.11 3.21 0.005
≥1 rejection episode 1.85
 No Ref
 Yes −6.69 2.82 0.019
Interaction time and ipsilateral calcification 1.96
 Day 1 – Day 50: Ipsilateral calcification score −0.32 0.23 0.179
 Day 50 – Day 100: Ipsilateral calcification score −0.26 0.36 0.468
 After Day 100: Ipsilateral calcification score −0.47 0.19 0.014

ABOi, ABO incompatible; DBD, donation after brain death; DCD, donation after circulatory death; eGFR, estimated glomerular filtration rate; HLA, human leukocyte antigen; HLAi, human leukocyte antigen incompatible; vPRA, virtual panel reactive antibodies.